1
/
of
1
Elabscience
SKU:PKSH032633
Recombinant Human Interleukin-22/IL-22 Protein (C-hIgG4 Fc)
Recombinant Human Interleukin-22/IL-22 Protein (C-hIgG4 Fc)
Regular price
$200.00 USD
Regular price
Sale price
$200.00 USD
Unit price
/
per
Shipping calculated at checkout.
Couldn't load pickup availability
Introducing the Recombinant Human Interleukin-22/IL-22 Protein (C-hIgG4 Fc), a cutting-edge biotechnological advancement in the field of immunology. This meticulously engineered protein, derived from human sources, showcases remarkable potential in therapeutic applications.
The Recombinant Human Interleukin-22/IL-22 Protein (C-hIgG4 Fc) is a fusion protein that combines the potent bioactivity of Interleukin-22 (IL-22) with the enhanced stability and prolonged half-life provided by the C-terminal region of human IgG4 Fc. This fusion protein exhibits exceptional binding affinity to the IL-22 receptor, thereby facilitating its therapeutic efficacy.
IL-22, a member of the IL-10 cytokine family, plays a pivotal role in regulating tissue homeostasis and immune responses. By activating the JAK-STAT signaling pathway, IL-22 exerts its multifaceted effects on various target cells, including epithelial cells, hepatocytes, and immune cells. This protein has been implicated in the modulation of inflammation, tissue repair, and host defense against pathogens.
The fusion of IL-22 with the C-terminal region of human IgG4 Fc confers several advantages to this recombinant protein. Firstly, it enhances the stability and solubility of IL-22, ensuring its optimal functionality. Additionally, the IgG4 Fc region prolongs the half-life of IL-22, thereby extending its therapeutic window and reducing the frequency of administration.
The Recombinant Human Interleukin-22/IL-22 Protein (C-hIgG4 Fc) holds immense promise in the treatment of various inflammatory and autoimmune disorders. Its ability to modulate immune responses and promote tissue repair makes it an attractive candidate for therapeutic interventions targeting conditions such as psoriasis, inflammatory bowel disease, and rheumatoid arthritis.
Furthermore, this recombinant protein exhibits exceptional purity and bioactivity, owing to its stringent manufacturing process and rigorous quality control measures. Each batch undergoes meticulous characterization, ensuring consistent and reliable performance.
In conclusion, the Recombinant Human Interleukin-22/IL-22 Protein (C-hIgG4 Fc) represents a groundbreaking advancement in the realm of immunotherapy. Its fusion of IL-22 with the C-terminal region of human IgG4 Fc confers enhanced stability, prolonged half-life, and remarkable therapeutic potential. With its multifaceted effects on immune regulation and tissue
The Recombinant Human Interleukin-22/IL-22 Protein (C-hIgG4 Fc) is a fusion protein that combines the potent bioactivity of Interleukin-22 (IL-22) with the enhanced stability and prolonged half-life provided by the C-terminal region of human IgG4 Fc. This fusion protein exhibits exceptional binding affinity to the IL-22 receptor, thereby facilitating its therapeutic efficacy.
IL-22, a member of the IL-10 cytokine family, plays a pivotal role in regulating tissue homeostasis and immune responses. By activating the JAK-STAT signaling pathway, IL-22 exerts its multifaceted effects on various target cells, including epithelial cells, hepatocytes, and immune cells. This protein has been implicated in the modulation of inflammation, tissue repair, and host defense against pathogens.
The fusion of IL-22 with the C-terminal region of human IgG4 Fc confers several advantages to this recombinant protein. Firstly, it enhances the stability and solubility of IL-22, ensuring its optimal functionality. Additionally, the IgG4 Fc region prolongs the half-life of IL-22, thereby extending its therapeutic window and reducing the frequency of administration.
The Recombinant Human Interleukin-22/IL-22 Protein (C-hIgG4 Fc) holds immense promise in the treatment of various inflammatory and autoimmune disorders. Its ability to modulate immune responses and promote tissue repair makes it an attractive candidate for therapeutic interventions targeting conditions such as psoriasis, inflammatory bowel disease, and rheumatoid arthritis.
Furthermore, this recombinant protein exhibits exceptional purity and bioactivity, owing to its stringent manufacturing process and rigorous quality control measures. Each batch undergoes meticulous characterization, ensuring consistent and reliable performance.
In conclusion, the Recombinant Human Interleukin-22/IL-22 Protein (C-hIgG4 Fc) represents a groundbreaking advancement in the realm of immunotherapy. Its fusion of IL-22 with the C-terminal region of human IgG4 Fc confers enhanced stability, prolonged half-life, and remarkable therapeutic potential. With its multifaceted effects on immune regulation and tissue
Share
